RFID’s Possible Interaction With Biologics Queried By Biogen, Pfizer
Executive Summary
Radiofrequency identification appears to hold the most potential to increase the security of the pharmaceutical supply chain, stakeholders advise FDA, but important questions include how the radiofrequency emissions might interact with biologics and certain other kinds of drug products
You may also be interested in...
EU Tackles Counterfeits, But Parallel Trade Poses Tough Issues
Tackling counterfeit drugs is one pillar of the European Commission's package of new proposed pharmaceutical legislation. It will mean higher costs for most drug firms, while significant loopholes will remain
EU Tackles Counterfeits, But Parallel Trade Poses Tough Issues
Tackling counterfeit drugs is one pillar of the European Commission's package of new proposed pharmaceutical legislation. It will mean higher costs for most drug firms, while significant loopholes will remain
RFID tracking and privacy workshop
Emerging uses of radiofrequency identification technology and implications for consumer protection is the subject of a Sept. 23 workshop being convened by Federal Trade Commission staff. The session will bring together industry, government and consumer representatives from Europe and the U.S. to discuss security and privacy concerns associated with RFID. The technology is seen by some drug makers as having the potential to increase security of the pharmaceutical supply chain, and the growing utilization of item-level tagging in the retail sector is on the agenda (1"The Pink Sheet," June 16, 2008, p. 16)